Liver X receptors at the intersection of lipid metabolism and atherogenesis

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 29-36

  Lee, Stephen D ^a   Tontonoz, Peter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Lipid metabolism; LXR; Nuclear receptor

Indexed keywords

CHOLESTEROL; LIVER X RECEPTOR; ABC TRANSPORTER A1; LIPOPROTEIN; ORPHAN NUCLEAR RECEPTOR;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG TARGETING; HUMAN; INFLAMMATION; INTESTINE; LIPID METABOLISM; LIPID TRANSPORT; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; AGONISTS; ANIMAL; COMPLICATION; DISEASE COURSE; HOMEOSTASIS; HYPERCHOLESTEROLEMIA; INTESTINE CELL; LIVER CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; SMALL INTESTINE; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL TRANSPORT; CHOLESTEROL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ENTEROCYTES; HEPATOCYTES; HOMEOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTESTINE, SMALL; LIPID METABOLISM; LIPOPROTEINS; LIVER X RECEPTORS; MACROPHAGES; MOLECULAR TARGETED THERAPY; ORPHAN NUCLEAR RECEPTORS; SIGNAL TRANSDUCTION;

EID: 84936757799     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.042     Document Type: Review

References (150)

1. Goldstein J.L., Brown M.S. Acentury of cholesterol and coronaries: from plaques to genes to statins. Cell 2015, 161:161-172.
2. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
3. Yusuf S., Rangarajan S., Teo K., et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N.Engl. J. Med. 2014, 371:818-827.
4. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
5. Breslow J.L. Mouse models of atherosclerosis. Sci. (New York, N.Y.) 1996, 272:685-688.
6. Zadelaar S., Kleemann R., Verschuren L., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1706-1721.
7. Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' Collaborators.
8. World Health Organization Global Burden of Disease 2008, 1-160. World Health Organization Press, Geneva.
9. Goldstein J.L., DeBose-Boyd R.A., Brown M.S. Protein sensors for membrane sterols. Cell 2006, 124:35-46.
10. Willy P.J., Umesono K., Ong E.S., et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
11. Auboeuf D., Rieusset J., Fajas L., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
12. Apfel R., Benbrook D., Lernhardt E., et al. Anovel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 1994, 14:7025-7035.
13. Molteni V., Li X., Nabakka J., et al. N-acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J.Med. Chem. 2007, 50:4255-4259.
14. Svensson S., Ostberg T., Jacobsson M., et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22:4625-4633.
15. Hoerer S., Schmid A., Heckel A., et al. Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J.Mol. Biol. 2003, 334:853-861.
16. Williams S., Bledsoe R.K., Collins J.L., et al. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J.Biol. Chem. 2003, 278:27138-27143.
17. Janowski B.A., Grogan M.J., Jones S.A., et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA 1999, 96:266-271.
18. Peet D.J., Turley S.D., Ma W., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
19. Tontonoz P. Transcriptional and posttranscriptional control of cholesterol homeostasis by liver X receptors. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:129-137.
20. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000, 14:121-141.
21. Fu X., Menke J.G., Chen Y., et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J.Biol. Chem. 2001, 276:38378-38387.
22. Janowski B.A., Willy P.J., Devi T.R., et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
23. Lehmann J.M., Kliewer S.A., Moore L.B., et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J.Biol. Chem. 1997, 272:3137-3140.
24. Kalaany N.Y., Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev. Physiol. 2006, 68:159-191.
25. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 2013, 13:709-721.
26. Boadu E., Bilbey N.J., Francis G.A. Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation. Curr. Opin. Lipidol. 2008, 19:270-276.
27. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease - reply. N.Engl. J. Med. 2005, 353:429-430.
28. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
29. Tangirala R.K., Bischoff E.D., Joseph S.B., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA 2002, 99:11896-11901.
30. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 2002, 99:7604-7609.
31. Calkin A.C., Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1513-1518.
32. Libby P., Hansson G.K. Inflammation and immunity in diseases of the arterial tree players and layers. Circulation Res. 2015, 116:307-311.
33. Seimon T.A., Nadolski M.J., Liao X., et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010, 12:467-482.
34. Seimon T.A., Obstfeld A., Moore K.J., et al. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc. Natl. Acad. Sci. USA 2006, 103:19794-19799.
35. Stewart C.R., Stuart L.M., Wilkinson K., et al. CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11:155-161.
36. Zelcer N., Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J.Clin. Investig. 2006, 116:607-614.
37. Hong C., Walczak R., Dhamko H., et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J.Lipid Res. 2011, 52:531-539.
38. Joseph S.B., Castrillo A., Laffitte B.A., et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
39. Ogawa D., Stone J.F., Takata Y., et al. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ. Res. 2005, 96:e59-67.
40. Castrillo A., Joseph S.B., Vaidya S.A., et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 2003, 12:805-816.
41. Perissi V., Jepsen K., Glass C.K., et al. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11:109-123.
42. Westerterp M., Bochem A.E., Yvan-Charvet L., et al. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 2014, 114:157-170.
43. Tarling E.J., Vallim T.Q.D.A., Edwards P.A. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol. Metabol. TEM 2013, 24:342-350.
44. Rong X., Albert C.J., Hong C., et al. LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell. Metab. 2013, 18:685-697.
45. Maxwell K.N., Soccio R.E., Duncan E.M., et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J.Lipid Res. 2003, 44:2109-2119.
46. Joseph S.B., Bradley M.N., Castrillo A., et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004, 119:299-309.
47. Arai S., Shelton J.M., Chen M., et al. Arole for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005, 1:201-213.
48. Hamada M., Nakamura M., Tran M.T.N., et al. MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. Nat. Commun. 2014, 5:3147.
49. Sallam T., Ito A., Rong X., et al. The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis. J.Lipid Res. 2014, 55:1120-1130.
50. Kitchens R.L., Thompson P.A. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J.Endotoxin Res. 2005, 11:225-229.
51. Lamping N., Dettmer R., Schroder N.W., et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J.Clin. Investig. 1998, 101:2065-2071.
52. Baldan A., Pei L., Lee R., et al. Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2301-2307.
53. Ranalletta M., Wang N., Han S., et al. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2308-2315.
54. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2255-2264.
55. Zelcer N., Hong C., Boyadjian R., et al. LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL receptor. Sci. (New York, N.Y.) 2009, 325:100-104.
56. Calkin A.C., Goult B.T., Zhang L., et al. FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proc. Natl. Acad. Sci. USA 2011, 108:20107-20112.
57. Zhang L., Reue K., Fong L.G., et al. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2541-2546.
58. Zhang L., Fairall L., Goult B.T., et al. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev. 2011, 25:1262-1274.
59. Zhang L., Xu M., Scotti E., et al. Both K63 and K48 ubiquitin linkages signal lysosomal degradation of the LDL receptor. J.Lipid Res. 2013, 54:1410-1420.
60. Hong C., Marshall S.M., McDaniel A.L., et al. The LXR-idol axis differentially regulates plasma LDL levels in primates and mice. Cell Metab. 2014, 20:910-918.
61. Scotti E., Hong C., Yoshinaga Y., et al. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol. Cell. Biol. 2011, 31:1885-1893.
62. Weissglas-Volkov D., Calkin A.C., Tusie-Luna T., et al. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. J.Clin. Investig. 2011, 121:3062-3071.
63. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
64. Sorrentino V., Fouchier S.W., Motazacker M.M., et al. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. Eur. Heart J. 2013, 34:1292-1297.
65. Levin N., Bischoff E.D., Daige C.L., et al. Macrophage liver x receptor is required for antiatherogenic activity of LXR agonists. Arter. Thromb. Vasc. 2005, 25:135-142.
66. Teupser D., Kretzschmar D., Tennert C., et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arter. Thromb. Vasc. 2008, 28:2009-2015.
67. Feig J.E., Pineda-Torra I., Sanson M., et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J.Clin. Investig. 2010, 120:4415-4424.
68. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22:336-345.
69. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 1999, 22:352-355.
70. Bodzioch M., Orsó E., Klucken J., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 1999, 22:347-351.
71. Remaley A.T., Schumacher U.K., Stonik J.A., et al. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1813-1821.
72. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J.Clin. Investig. 1995, 96:78-87.
73. Costet P., Luo Y., Wang N., et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J.Biol. Chem. 2000, 275:28240-28245.
74. Venkateswaran A., Laffitte B.A., Joseph S.B., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA 2000, 97:12097-12102.
75. Klucken J., Buchler C., Orso E., et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. USA 2000, 97:817-822.
76. Kennedy M.A., Barrera G.C., Nakamura K., et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell. Metab. 2005, 1:121-131.
77. Wang N., Lan D.B., Chen W.G., et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA 2004, 101:9774-9779.
78. Nakamura K., Kennedy M.A., Baldan A., et al. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J.Biol. Chem. 2004, 279:45980-45989.
79. Sankaranarayanan S., Oram J.F., Asztalos B.F., et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J.Lipid Res. 2009, 50:275-284.
80. Tarling E.J., Edwards P.A. Dancing with the sterols: critical roles for ABCG1, ABCA1, miRNAs, and nuclear and cell surface receptors in controlling cellular sterol homeostasis. Biochim. Biophys. Acta 2012, 1821:386-395.
81. Tarling E.J., Edwards P.A. ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc. Natl. Acad. Sci. USA 2011, 108:19719-19724.
82. Aiello R.J., Brees D., Bourassa P.A., et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arter. Thromb. Vasc. 2002, 22:630-637.
83. Bi X., Zhu X., Gao C., et al. Myeloid cell-specific ATP-binding cassette transporter A1 deletion has minimal impact on atherogenesis in atherogenic diet-fed low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1888-1899.
84. Zhao Y., Pennings M., Hildebrand R.B., et al. Enhanced foam cell formation, atherosclerotic lesion development, and inflammation by combined deletion of ABCA1 and SR-BI in bone marrow-derived cells in LDL receptor knockout mice on western-type diet. Circ. Res. 2010, 107. E20-+.
85. Out R., Hoekstra M., Habets K., et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arter. Thromb. Vasc. 2008, 28:258-264.
86. Van Eck M., Bos I.S.T., Kaminski W.E., et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl. Acad. Sci. USA 2002, 99:6298-6303.
87. Yvan-Charvet L., Ranalletta M., Wang N., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J.Clin. Investig. 2007, 117:3900-3908.
88. Brunham L.R., Singaraja R.R., Duong M., et al. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:548-554.
89. Mak P.A., Laffitte B.A., Desrumaux C., et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J.Biol. Chem. 2002, 277:31900-31908.
90. Laffitte B.A., Repa J.J., Joseph S.B., et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA 2001, 98:507-512.
91. Breevoort S.R., Angdisen J., Schulman I.G. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1650-1660.
92. Lo Sasso G., Murzilli S., Salvatore L., et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell. Metab. 2010, 12:187-193.
93. Yasuda T., Grillot D., Billheimer J.T., et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport invivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:781-786.
94. Peng D.C., Hiipakka R.A., Dai Q., et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J.Pharmacol. Exp. Ther. 2008, 327:332-342.
95. Brunham L.R., Kruit J.K., Pape T.D., et al. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ. Res. 2006, 99:672-674.
96. Brunham L.R., Kruit J.K., Iqbal J., et al. Intestinal ABCA1 directly contributes to HDL biogenesis invivo. J.Clin. Investig. 2006, 116:1052-1062.
97. Zannis V.I., Chroni A., Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J.Mol. Med-Jmm. 2006, 84:276-294.
98. Luo Y., Tall A.R. Sterol upregulation of human CETP expression invitro and in transgenic mice by an LXR element. J.Clin. Investig. 2000, 105:513-520.
99. Tanigawa H., Billheimer J.T., Tohyama J.I., et al. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 2007, 116:1267-1273.
100. Laffitte B.A., Joseph S.B., Chen M., et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 2003, 23:2182-2191.
101. Cao G., Beyer T.P., Yang X.P., et al. Phospholipid transfer protein is regulated by liver X receptors invivo. J.Biol. Chem. 2002, 277:39561-39565.
102. Mak P.A., Kast-Woelbern H.R., Anisfeld A.M., et al. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J.Lipid Res. 2002, 43:2037-2041.
103. Lakomy D., Rebe C., Sberna A.L., et al. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1923-1929.
104. Albers J.J., Vuletic S., Cheung M.C. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Bba-Mol Cell. Biol. L 2012, 1821:345-357.
105. Desrumaux C., Deckert V., Athias A., et al. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 1999, 13:883-892.
106. Ogier N., Klein A., Deckert V., et al. Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol supplementation. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2407-2412.
107. Masson D., Jiang X.C., Lagrost L., et al. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J.Lipid Res. 2009, 50(Suppl.l):S201-S206.
108. Moerland M., Samyn H., van Gent T., et al. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1277-1282.
109. Calkin A.C., Lee S.D., Kim J., et al. Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice. Circ. Res. 2014, 115:442-449.
110. Versmissen J., Oosterveer D.M., Hoekstra M., et al. Apolipoprotein isoform E4 does not increase coronary heart disease risk in carriers of low-density lipoprotein receptor mutations. Circ. Cardiovasc. Genet. 2011, 4:655-660.
111. Trigatti B.L., Krieger M., Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1732-1738.
112. Fabre A.C., Malaval C., Ben Addi A., et al. P2Y13 receptor is critical for reverse cholesterol transport. Hepatol. Baltim. Md. 2010, 52:1477-1483.
113. Bultel S., Helin L., Clavey V., et al. Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2288-2295.
114. Davis C.G., Goldstein J.L., Südhof T.C., et al. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 1987, 326:760-765.
115. Carstea E.D., Morris J.A., Coleman K.G., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Sci. (New York, N.Y.) 1997, 277:228-231.
116. Naureckiene S., Sleat D.E., Lackland H., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Sci. (New York, N.Y.) 2000, 290:2298-2301.
117. Rigamonti E., Helin L., Lestavel S., et al. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 2005, 97:682-689.
118. Ishibashi M., Varin A., Filomenko R., et al. Liver x receptor regulates arachidonic acid distribution and eicosanoid release in human macrophages: a key role for lysophosphatidylcholine acyltransferase 3. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1171-1179.
119. Zhao Y., Chen Y.Q., Bonacci T.M., et al. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J.Biol. Chem. 2008, 283:8258-8265.
120. Hishikawa D., Shindou H., Kobayashi S., et al. Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proc. Natl. Acad. Sci. USA 2008, 105:2830-2835.
121. Rong X., Wang B., Dunham M.M., et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife 2015, 4.
122. Repa J.J., Berge K.E., Pomajzl C., et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J.Biol. Chem. 2002, 277:18793-18800.
123. Wang J., Mitsche M.A., Lutjohann D., et al. Relative roles of ABCG5/ABCG8 in liver and intestine. J.Lipid Res. 2015, 56:319-330.
124. Dikkers A., Freak de Boer J., Annema W., et al. Scavenger receptor BI and ABCG5/G8 differentially impact biliary sterol secretion and reverse cholesterol transport in mice. Hepatol. Baltim. Md. 2013, 58:293-303.
125. Wiersma H., Gatti A., Nijstad N., et al. Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Hepatol. Baltim. Md. 2009, 50:1263-1272.
126. Plosch T., van der Veen J.N., Havinga R., et al. Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G414-G423.
127. Yu L., York J., von Bergmann K., et al. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J.Biol. Chem. 2003, 278:15565-15570.
128. Lee S.D., Gershkovich P., Darlington J.W., et al. Inhibition of cholesterol absorption: targeting the intestine. Pharm. Res. 2012, 29:3235-3250.
129. Bonamassa B., Moschetta A. Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol. Metabol.: TEM 2013, 24:120-128.
130. Borgstrom B. Studies on intestinal cholesterol absorption in the human. J.Clin. Investig. 1960, 39:809-815.
131. Stitziel N.O., Won H.H., et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N.Engl. J. Med. 2014, 371:2072-2082. Myocardial Infarction Genetics Consortium, I.
132. Yu L., Li-Hawkins J., Hammer R.E., et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J.Clin. Investig. 2002, 110:671-680.
133. van der Veen J.N., van Dijk T.H., Vrins C.L., et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J.Biol. Chem. 2009, 284:19211-19219.
134. Temel R.E., Brown J.M. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr. Opin. Lipidol. 2012, 23:85-90.
135. Temel R.E., Sawyer J.K., Yu L., et al. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell. Metab. 2010, 12:96-102.
136. Le May C., Berger J.M., Lespine A., et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1484-1493.
137. Lee S.D., Thornton S.J., Sachs-Barrable K., et al. Evaluation of the contribution of the ATP binding cassette transporter, P-glycoprotein, to invivo cholesterol homeostasis. Mol. Pharm. 2013, 10:3203-3212.
138. Loren J., Huang Z., Laffitte B.A., et al. Liver X receptor modulators: a review of recently patented compounds. Expert Opin. Ther. Pat. 2009-2012, 2013(23):1317-1335.
139. Hong C., Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 2014, 13:433-444.
140. Rankinen T., Sarzynski M.A., Ghosh S., et al. Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors?. Circ. Res. 2015, 116:909-922.
141. Joseph S.B., Laffitte B.A., Patel P.H., et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J.Biol. Chem. 2002, 277:11019-11025.
142. Chu K., Miyazaki M., Man W.C., et al. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol. Cell. Biol. 2006, 26:6786-6798.
143. Beaven S.W., Matveyenko A., Wroblewski K., et al. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell. Metab. 2013, 18:106-117.
144. Repa J.J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
145. Bradley M.N., Hong C., Chen M., et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J.Clin. Investig. 2007, 117:2337-2346.
146. Kim G.H., Oh G.S., Yoon J., et al. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor. J.Clin. Investig. 2015, 125:183-193.
147. Calkin A.C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell. Biol. 2012, 13:213-224.
148. Rebe C., Raveneau M., Chevriaux A., et al. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ. Res. 2009, 105:393-401.
149. A-Gonzalez N., Bensinger S.J., Hong C., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31:245-258.
150. Castrillo A., Joseph S.B., Marathe C., et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J.Biol. Chem. 2003, 278:10443-10449.